cytokines

Prediction of IL2 inducing peptides

Single-cell transcriptomic profiling of CAR T cells expressing synthetic receptors, termed "velocity CAR T" cells.

Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines

Code associated with 'Cytokine signature clusters as a tool to compare changes associated with tobacco product use in upper and lower airway samples' published in 2022 (PMID: 35318855).

scRNA-seq analysis of cardiac immune cells in heart failure. 12 figures. Gja1/Cx43 cardio-immune interface.

Theoretical analysis code for antigen encoding from cytokine dynamics.

Final project computational methods: Analysis of cytokines IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10 and TNFα levels in different groups. Status: finished

science text

Synthekine is a clinical-stage biotechnology company discovering, developing, and commercializing the next generation of selective cytokine therapeutics. The company believes cytokine therapeutics engineered to be selective can fundamentally change the treatment paradigm for cancer and inflammatory disease.

Medikine is a clinical-stage biopharmaceutical company based in San Diego, California, engineering a new class of medicines called PEPTIKINES — synthetic peptide mimetics of cytokines and growth-factor receptor agonists.